204 related articles for article (PubMed ID: 20194855)
1. Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials.
du Bois A; Reuss A; Harter P; Pujade-Lauraine E; Ray-Coquard I; Pfisterer J; ;
J Clin Oncol; 2010 Apr; 28(10):1733-9. PubMed ID: 20194855
[TBL] [Abstract][Full Text] [Related]
2. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO).
du Bois A; Reuss A; Pujade-Lauraine E; Harter P; Ray-Coquard I; Pfisterer J
Cancer; 2009 Mar; 115(6):1234-44. PubMed ID: 19189349
[TBL] [Abstract][Full Text] [Related]
3. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial.
Panici PB; Maggioni A; Hacker N; Landoni F; Ackermann S; Campagnutta E; Tamussino K; Winter R; Pellegrino A; Greggi S; Angioli R; Manci N; Scambia G; Dell'Anna T; Fossati R; Floriani I; Rossi RS; Grassi R; Favalli G; Raspagliesi F; Giannarelli D; Martella L; Mangioni C
J Natl Cancer Inst; 2005 Apr; 97(8):560-6. PubMed ID: 15840878
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
Wimberger P; Lehmann N; Kimmig R; Burges A; Meier W; Du Bois A;
Gynecol Oncol; 2007 Jul; 106(1):69-74. PubMed ID: 17397910
[TBL] [Abstract][Full Text] [Related]
5. Does systematic lymphadenectomy have a benefit on survival of suboptimally debulked patients with stage III ovarian carcinoma? A DEGOG* Study.
Saygili U; Guclu S; Uslu T; Erten O; Ture S; Demir N
J Surg Oncol; 2002 Nov; 81(3):132-7. PubMed ID: 12407725
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer.
Chang SJ; Bristow RE; Ryu HS
Gynecol Oncol; 2012 Sep; 126(3):381-6. PubMed ID: 22609747
[TBL] [Abstract][Full Text] [Related]
7. Role of lymphadenectomy in the management of grossly apparent advanced stage epithelial ovarian cancer.
Aletti GD; Dowdy S; Podratz KC; Cliby WA
Am J Obstet Gynecol; 2006 Dec; 195(6):1862-8. PubMed ID: 17132488
[TBL] [Abstract][Full Text] [Related]
8. Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group).
Wimberger P; Wehling M; Lehmann N; Kimmig R; Schmalfeldt B; Burges A; Harter P; Pfisterer J; du Bois A
Ann Surg Oncol; 2010 Jun; 17(6):1642-8. PubMed ID: 20165986
[TBL] [Abstract][Full Text] [Related]
9. Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum/paclitaxel-containing first-line chemotherapy: an exploratory analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group.
Fotopoulou C; duBois A; Karavas AN; Trappe R; Aminossadati B; Schmalfeldt B; Pfisterer J; Sehouli J;
J Clin Oncol; 2008 Jun; 26(16):2683-9. PubMed ID: 18509180
[TBL] [Abstract][Full Text] [Related]
10. [Effect of retroperitoneal lymphadenectomy on survival of patients with epithelial ovarian cancer].
Xiong ZF; Wang ZH; Wang SX
Zhonghua Fu Chan Ke Za Zhi; 2003 Feb; 38(2):77-80. PubMed ID: 12783692
[TBL] [Abstract][Full Text] [Related]
11. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.
Trimbos JB; Vergote I; Bolis G; Vermorken JB; Mangioni C; Madronal C; Franchi M; Tateo S; Zanetta G; Scarfone G; Giurgea L; Timmers P; Coens C; Pecorelli S;
J Natl Cancer Inst; 2003 Jan; 95(2):113-25. PubMed ID: 12529344
[TBL] [Abstract][Full Text] [Related]
12. The clinical outcome of epithelial ovarian cancer patients with apparently isolated lymph node recurrence: a multicenter retrospective Italian study.
Gadducci A; Cosio S; Zola P; Sostegni B; Ferrero AM; Teti G; Cristofani R; Sartori E
Gynecol Oncol; 2010 Mar; 116(3):358-63. PubMed ID: 19954826
[TBL] [Abstract][Full Text] [Related]
13. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens.
du Bois A; Weber B; Rochon J; Meier W; Goupil A; Olbricht S; Barats JC; Kuhn W; Orfeuvre H; Wagner U; Richter B; Lueck HJ; Pfisterer J; Costa S; Schroeder W; Kimmig R; Pujade-Lauraine E; ; ;
J Clin Oncol; 2006 Mar; 24(7):1127-35. PubMed ID: 16505432
[TBL] [Abstract][Full Text] [Related]
14. Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial.
Crawford SC; Vasey PA; Paul J; Hay A; Davis JA; Kaye SB
J Clin Oncol; 2005 Dec; 23(34):8802-11. PubMed ID: 16314640
[TBL] [Abstract][Full Text] [Related]
15. Cytoreductive surgery in advanced epithelial cancer of the ovary: the impact of aortic and pelvic lymphadenectomy.
Spirtos NM; Gross GM; Freddo JL; Ballon SC
Gynecol Oncol; 1995 Mar; 56(3):345-52. PubMed ID: 7705667
[TBL] [Abstract][Full Text] [Related]
16. The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer.
Alvarez Secord A; Havrilesky LJ; Bae-Jump V; Chin J; Calingaert B; Bland A; Rutledge TL; Berchuck A; Clarke-Pearson DL; Gehrig PA
Gynecol Oncol; 2007 Nov; 107(2):285-91. PubMed ID: 17688923
[TBL] [Abstract][Full Text] [Related]
17. Lymph-vascular space invasion and number of positive para-aortic node groups predict survival in node-positive patients with endometrial cancer.
Watari H; Todo Y; Takeda M; Ebina Y; Yamamoto R; Sakuragi N
Gynecol Oncol; 2005 Mar; 96(3):651-7. PubMed ID: 15721407
[TBL] [Abstract][Full Text] [Related]
18. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial.
Benedetti Panici P; Basile S; Maneschi F; Alberto Lissoni A; Signorelli M; Scambia G; Angioli R; Tateo S; Mangili G; Katsaros D; Garozzo G; Campagnutta E; Donadello N; Greggi S; Melpignano M; Raspagliesi F; Ragni N; Cormio G; Grassi R; Franchi M; Giannarelli D; Fossati R; Torri V; Amoroso M; Crocè C; Mangioni C
J Natl Cancer Inst; 2008 Dec; 100(23):1707-16. PubMed ID: 19033573
[TBL] [Abstract][Full Text] [Related]
19. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial.
Harter P; du Bois A; Hahmann M; Hasenburg A; Burges A; Loibl S; Gropp M; Huober J; Fink D; Schröder W; Muenstedt K; Schmalfeldt B; Emons G; Pfisterer J; Wollschlaeger K; Meerpohl HG; Breitbach GP; Tanner B; Sehouli J; ;
Ann Surg Oncol; 2006 Dec; 13(12):1702-10. PubMed ID: 17009163
[TBL] [Abstract][Full Text] [Related]
20. Relationship between time interval from primary surgery to the start of taxane- plus platinum-based chemotherapy and clinical outcome of patients with advanced epithelial ovarian cancer: results of a multicenter retrospective Italian study.
Gadducci A; Sartori E; Landoni F; Zola P; Maggino T; Maggioni A; Cosio S; Frassi E; LaPresa MT; Fuso L; Cristofani R
J Clin Oncol; 2005 Feb; 23(4):751-8. PubMed ID: 15613698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]